

## 第 3 回 札幌国際がんシンポジウム

### テーマ

“Biological Responses in Cancer Chemotherapy”

### 日時

1983 年 7 月 14 日～16 日

### 会場

センチュリーロイヤルホテル（札幌市中央区）

### 代表世話人

桜井欽夫（癌研癌化療センター）

---

## The 3rd Sapporo International Cancer Symposium

### Theme:

“Biological Responses in Cancer Chemotherapy”

### Date:

July 14-16, 1983

### Venue:

Century Royal Hotel, Sapporo, Japan

### Organizing Committee(\*Chairperson):

Alexander Fefer, Seattle

Hiroshi Kobayashi, Sapporo

Enrico Mihich, Buffalo

Takeo Wada, Sapporo

Yoshio Sakurai\*, Tokyo

### Program:

Session I: Modification of Biological Responses

(Chairmen: T. Wada and Y. Sakurai)

Low molecular weight immunomodifiers produced by microorganisms.

H. Umezawa, Tokyo

Adoptive chemoimmunotherapy of murine tumors.

A. Fefer, Seattle

**Session IIA:** Modification of Biological Responses, Fundamental phenomena of negative response

(Chairmen, J.L. Turk and T. Tokunaga)

Immunosuppressive acidic protein (IAP) – A serum protein factor against self-defense in correlation with the appearance of suppressor macrophages.

N. Ishida, Sendai

Tumor enhancement by BCG cell walls(BCGcw) induced suppressor cells and its modification by pharmacologic treatment.

H.T. Wepsic et al, Chicago

**Session IIB:** Modification of Biological Responses, Elimination of negative responses

(Chairmen, S. Dray and M. Hosokawa)

The effect of cyclophosphamide on immunological control mechanisms.

J.L. Turk, London

Dissection of human immunoregulatory T cell network with in vitro active cyclophosphamide compounds.

S. Ozer, Buffalo

Augmentation of antitumor responses by busulfan and its feasibility in cancer therapy.

F. Sendo, Yamagata

**Session IIB(Continued):** Modification of Biological Responses, Elimination of negative responses

(Chairmen, A. Mantovani and F. Sendo)

Modulation of antitumor resistance by bleomycin.

M. Hosokawa et al, Sapporo

Immuno-modulating effects of the antitumor antibiotics, aclacinomycin, oxanosine, neothramycin, and mazethramycin.

M. Ishizuka, et al, Tokyo

Immunomodulation effects of cisplatinum.

B. Serrou & D. Cupissol, Montpellier

**Session IIC:** Modification of Biological Responses, Potentiation of positive responses

(Chairmen, F. Spreafico and N. Ishida)

Functional status of tumor associated inflammatory cells and their modulation by chemotherapeutic agents.

A. Mantovani, Milano

Induction and potentiation of phagocytic cell cytotoxicity by chemotherapeutic drugs.

M. Yamazaki et al, Sagamiko

Augmentation of host immunity responses by chemotherapeutic drugs.

E. Mihich, Bauffalo

Analysis of therapeutic effect of local chemoimmunotherapy.

T. Ogura, Osaka

**Session IIIA:** Efficacy of Modulated Biological Responses in Cancer Therapy,  
Experimental basis

(Chairmen, A. Fefer and T. Ogura)

6-Mercaptopurine-dependent inhibition of suppressor macrophages and potentiation  
of active immunotherapy.

T. Kataoka, Tokyo

The importance of immunomodulation by cytotoxic drugs for effective therapy of  
established tumors.

S. Dray & M. Mokyr, Chicago

**Session IIIA(Continued):** Efficacy of Modulated Biological Responses in Cancer  
Therapy, Experimental basis

(Chairmen, A. H.T. Wepsic and T. Kataoka)

In vivo efficacy of thymosin  $\alpha 1$  in immunosuppressed mice.

H. Ishitsuka et al, Kamakura

Potentiation of chemotherapy by thymosin pretreated bone marrow cells in tumor  
bearing mice.

B. Serrou et al, Montpellier

**Session IIIB:** Efficacy of Modulated Biological Responses in Cancer Therapy,  
Clinical possibility

(Chairmen, B. Serrou and A. Yachi)

Heterogeneity in susceptibility to cancer chemotherapeutic agents among  
immunocytes.

F. Spreafico, Milano

Intraleural instillation of *Nocardia rubra* cell wall skeleton in patients with lung cancer.

K. Yasumoto, Fukuoka

Bone marrow transplantation(BMT) for hematologic malignancies.

A. Fefer, Seattle

**Session IV: Genral Discussion**

(Chairmen, E. Mihich and H. Kobayashi)

Poster session:

Pattern analysis of electrophoretic mobility histogram of mouse thymocyte in drug evaluation.

T. Iwaguchi, Tokyo

The in vivo assessment of the capacity of BCGcw splenic suppressor cells to induce graft vs. host disease.

H.T. Wepsic et al, Chicago

Suppressor macrophages in tumor-bearing mice and their sensitivity to antineoplastic agents.

T. Kataoka, Tokyo

The effects of cyclophosphamide on the immune competent cells participating in the delayed hypersensitivity response in mice.

S. Morikawa et al, Izumo

Effect of ACNU on induction of cytotoxic T cells in the spleen of X-5563 tumor bearing mice.

S. Kurakata & K. Kitamura, Tokyo

Kinetics of alkylating activity in the blood after cyclophosphamide treatment for enhancement of delayed hypersensitivity.

A. Mitsuoka et al, Kyoto

Efficacy of chemotherapy combined with plasmaphoresis in human and rat cancer.

K. Orita, Okayama

Histological response in tumor tissue of cancer patients after chemotherapy.

A. Wakui et al, Sendai

Immunochemotherapy of experimental tumors by a combination of a protein-bound polysaccharide(PS-K) and cyclophosphamide.

M. Hosokawa et al, Sapporo

Cancer immunotherapy by phospholipids and glycolipids.

I. Kudo et al, Tokyo

Analysis of natural killer activity and antibody- dependent cellular cytotoxicity in patients with carcinoma of the lung.

N. Saijo et al, Tokyo

The analysis of cytostatic activity of human peripheral blood granulocytes and its augmentation with Nocardia rubra celliwall skeleton(N-CWS).

E. Shimizu et al, Tokyo

Effect of cyclophosphamide and forphenicicol on growth of and immunity to syngeneic mouse tumor.

K. Nitta & T. Tanaka, Tokyo

Induction of antitumor immune responses in T-cell depressed SHR rats by treatment with Thymosin Fr-5.

N. Takeichi et al, Sapporo

Cyclophosphamide-mediated selective elimination of suppressor cell activity from the spleen of mice bearing a large MOPC-315 plasmacytoma.

M. Mokyr & S. Dray, Chicago

Local immunochemotherapy of peritonitis carcinomatosa in mice by OK-432 and adriamycin or mitomycin C.

N. Yuki et al, Sapporo

Active fragments of thymosin  $\alpha$ 1: Immunorestitution in mice treated with chemotherapeutic agents.

Y. Ohta et al, Kamakura